Wilson M Compton1, Beth Han2, Christopher M Jones3, Carlos Blanco4. 1. National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Blvd., Bethesda, MD, 20892, USA. Electronic address: wcompton@nida.nih.gov. 2. Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Rockville, MD, 20857, USA. 3. Centers for Disease Control and Prevention, Atlanta, GA, 30341, USA. 4. National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Blvd., Bethesda, MD, 20892, USA.
Abstract
BACKGROUND: Using U.S. National Surveys on Drug Use and Health (NSDUH) data, researchers found that prevalence of cannabis use among adults increased in recent years, but prevalence of DSM-IV cannabis use disorder (CUD) was stable. Examining trends of all individual CUD criteria and of CUD severity may elucidate reasons for the lack of increases in CUD. METHODS: Data were from 749,500 persons aged 18 or older who participated in the 2002-2017 NSDUH. Descriptive analyses and logistic regressions were applied. RESULTS: Among adults during 2002-2017, past-year prevalence of DSM-IV CUD remained stable at 1.5% to 1.4%, but cannabis use increased from 10.4% to 15.3%, daily/near daily use increased from 1.9% to 4.2%, and mild DSM-5 CUD increased from 1.4% to 1.9%. Among adult cannabis users, past-year prevalence of DSM-IV CUD decreased from 14.8% to 9.3%, daily/near daily use increased from 18.0% to 27.2%, and DSM-5 moderate (4-5 criteria) and severe (6+ criteria) CUD decreased from 4.3% to 3.1% and from 2.4% to 1.3%, respectively. Examining trends in individual CUD criteria during 2002-2017 among adults overall revealed increases in two criteria (tolerance; spending a lot of time getting/using cannabis or getting over cannabis effects) and decreases/no changes in other criteria; among adult cannabis users, there was no change in one criterion (tolerance) and decreases in other criteria. CONCLUSIONS: DSM-5's single dimension CUD measure may be more sensitive to diagnosis prevalence changes than the separate DSM-IV cannabis dependence and abuse categories. Future diagnostic approaches to assessing CUD may benefit from quantitatively oriented criteria. Published by Elsevier B.V.
BACKGROUND: Using U.S. National Surveys on Drug Use and Health (NSDUH) data, researchers found that prevalence of cannabis use among adults increased in recent years, but prevalence of DSM-IV cannabis use disorder (CUD) was stable. Examining trends of all individual CUD criteria and of CUD severity may elucidate reasons for the lack of increases in CUD. METHODS: Data were from 749,500 persons aged 18 or older who participated in the 2002-2017 NSDUH. Descriptive analyses and logistic regressions were applied. RESULTS: Among adults during 2002-2017, past-year prevalence of DSM-IV CUD remained stable at 1.5% to 1.4%, but cannabis use increased from 10.4% to 15.3%, daily/near daily use increased from 1.9% to 4.2%, and mild DSM-5 CUD increased from 1.4% to 1.9%. Among adult cannabis users, past-year prevalence of DSM-IV CUD decreased from 14.8% to 9.3%, daily/near daily use increased from 18.0% to 27.2%, and DSM-5 moderate (4-5 criteria) and severe (6+ criteria) CUD decreased from 4.3% to 3.1% and from 2.4% to 1.3%, respectively. Examining trends in individual CUD criteria during 2002-2017 among adults overall revealed increases in two criteria (tolerance; spending a lot of time getting/using cannabis or getting over cannabis effects) and decreases/no changes in other criteria; among adult cannabis users, there was no change in one criterion (tolerance) and decreases in other criteria. CONCLUSIONS: DSM-5's single dimension CUD measure may be more sensitive to diagnosis prevalence changes than the separate DSM-IV cannabis dependence and abuse categories. Future diagnostic approaches to assessing CUD may benefit from quantitatively oriented criteria. Published by Elsevier B.V.
Entities:
Keywords:
Cannabis use; Cannabis use disorder; DSM-5; DSM-IV; Diagnostic criteria for cannabis use disorder
Authors: Deborah S Hasin; Charles P O'Brien; Marc Auriacombe; Guilherme Borges; Kathleen Bucholz; Alan Budney; Wilson M Compton; Thomas Crowley; Walter Ling; Nancy M Petry; Marc Schuckit; Bridget F Grant Journal: Am J Psychiatry Date: 2013-08 Impact factor: 18.112
Authors: Wilson M Compton; Beth Han; Christopher M Jones; Carlos Blanco; Arthur Hughes Journal: Lancet Psychiatry Date: 2016-08-31 Impact factor: 27.083
Authors: Deborah S Hasin; Bradley T Kerridge; Tulshi D Saha; Boji Huang; Roger Pickering; Sharon M Smith; Jeesun Jung; Haitao Zhang; Bridget F Grant Journal: Am J Psychiatry Date: 2016-03-04 Impact factor: 18.112
Authors: Deborah S Hasin; Katherine M Keyes; Donald Alderson; Shuang Wang; Efrat Aharonovich; Bridget F Grant Journal: J Clin Psychiatry Date: 2008-09-09 Impact factor: 4.384
Authors: Deborah S Hasin; Tulshi D Saha; Bradley T Kerridge; Risë B Goldstein; S Patricia Chou; Haitao Zhang; Jeesun Jung; Roger P Pickering; W June Ruan; Sharon M Smith; Boji Huang; Bridget F Grant Journal: JAMA Psychiatry Date: 2015-12 Impact factor: 21.596
Authors: Deborah S Hasin; Andrew J Saxon; Carol Malte; Mark Olfson; Katherine M Keyes; Jaimie L Gradus; Magdalena Cerdá; Charles C Maynard; Salomeh Keyhani; Silvia S Martins; David S Fink; Ofir Livne; Zachary Mannes; Melanie M Wall Journal: Am J Psychiatry Date: 2022-07-28 Impact factor: 19.242
Authors: Ryan K McBain; Eunice C Wong; Joshua Breslau; Amy L Shearer; Matthew S Cefalu; Elizabeth Roth; M Audrey Burnam; Rebecca L Collins Journal: Drug Alcohol Depend Date: 2020-07-24 Impact factor: 4.492
Authors: Rachel Carmen Ceasar; Alex H Kral; Kelsey Simpson; Lynn Wenger; Jesse L Goldshear; Ricky N Bluthenthal Journal: Drug Alcohol Depend Date: 2020-11-23 Impact factor: 4.492